{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T20:01:42Z","timestamp":1787256102289,"version":"build-2736575974"},"reference-count":97,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T00:00:00Z","timestamp":1716768000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Myasthenia gravis (MG) is an antibody-mediated autoimmune disease with a prevalence of 150\u2013250 cases per million individuals. Autoantibodies include long-lived antibodies against the acetylcholine receptor (AChR), mainly of the IgG1 subclass, and IgG4, produced almost exclusively by short-lived plasmablasts, which are prevalent in muscle-specific tyrosine kinase (MuSK) myasthenia gravis. Numerous investigations have demonstrated that MG patients receiving conventional medication today still do not possess satisfactory symptom control, indicating a substantial disease burden. Subsequently, based on the type of the autoantibody and the pathogenesis, we synthesized the published material to date and reached a conclusion regarding the literature related to personalized targeted therapy for MG. Novel agents for AChR MG have shown their efficacy in clinical research, such as complement inhibitors, FcRn receptor antagonists, and B-cell activating factor (BAFF) inhibitors. Rituximab, a representative drug of anti-CD20 therapy, has demonstrated benefits in treatment of MuSK MG patients. Due to the existence of low-affinity antibodies or unidentified antibodies that are inaccessible by existing methods, the treatment for seronegative MG remains complicated; thus, special testing and therapy considerations are necessary. It may be advantageous to initiate the application of novel biologicals at an early stage of the disease. Currently, therapies can also be combined and individualized according to different types of antibodies. With such a wide range of drugs, how to tailor treatment strategies to patients with various conditions and find the most suitable solution for each MG profile are our necessary and urgent aims.<\/jats:p>","DOI":"10.3389\/fphar.2024.1370411","type":"journal-article","created":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T04:16:41Z","timestamp":1716783401000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["Advancements and prospects of novel biologicals for myasthenia gravis: toward personalized treatment based on autoantibody specificities"],"prefix":"10.3389","volume":"15","author":[{"given":"Chi","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benqiao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingying","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruixia","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,5,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/s41577-019-0244-2","article-title":"B cell memory: building two walls of protection against pathogens","volume":"20","author":"Akkaya","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.3390\/jcm11061597","article-title":"Current treatment of myasthenia gravis","volume":"11","author":"Alhaidar","year":"2022","journal-title":"J. Clin. Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1002\/acn3.314","article-title":"Rituximab in refractory myasthenia gravis: a prospective, open-label study with long-term follow-up","volume":"3","author":"Anderson","year":"2016","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/s00415-010-5746-6","article-title":"Current approach to seronegative myasthenia","volume":"258","author":"Argov","year":"2011","journal-title":"J. Neurol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1212\/WNL.0b013e31821e5505","article-title":"Comparison of IVIg and PLEX in patients with myasthenia gravis","volume":"76","author":"Barth","year":"2011","journal-title":"Neurology"},{"key":"B6","doi-asserted-by":"publisher","first-page":"805697","DOI":"10.3389\/fimmu.2022.805697","article-title":"New and old anti-CD20 monoclonal antibodies for nephrotic syndrome. Where we are?","volume":"13","author":"Basu","year":"2022","journal-title":"Front. Immunol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s40265-019-1065-0","article-title":"Therapies directed against B-cells and downstream effectors in generalized autoimmune myasthenia gravis: current status","volume":"79","author":"Beecher","year":"2019","journal-title":"Drugs"},{"key":"B8","doi-asserted-by":"publisher","first-page":"12943","DOI":"10.1073\/pnas.2004325117","article-title":"FcRn, but not Fc\u03b3Rs, drives maternal-fetal transplacental transport of human IgG antibodies","volume":"117","author":"Borghi","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B9","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1001\/jamaneurol.2020.0851","article-title":"Comparison between rituximab treatment for new-onset generalized myasthenia gravis and refractory generalized myasthenia gravis","volume":"77","author":"Brauner","year":"2020","journal-title":"JAMA Neurol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S1474-4422(23)00077-7","article-title":"Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study","volume":"22","author":"Bril","year":"2023","journal-title":"Lancet Neurol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/nyas.14195","article-title":"Myasthenia gravis and specific immunotherapy: monoclonal antibodies","volume":"1452","author":"Cai","year":"2019","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"B12","doi-asserted-by":"publisher","first-page":"159","DOI":"10.3389\/fnmol.2020.00159","article-title":"Myasthenia gravis with antibodies against muscle specific kinase: an update on clinical features, pathophysiology and treatment","volume":"13","author":"Cao","year":"2020","journal-title":"Front. Mol. Neurosci."},{"key":"B13","doi-asserted-by":"publisher","first-page":"2843","DOI":"10.1172\/JCI29894","article-title":"Myasthenia gravis: past, present, and future","volume":"116","author":"Conti-Fine","year":"2006","journal-title":"J. Clin. Investig."},{"key":"B14","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1002\/acn3.51492","article-title":"Drug-refractory myasthenia gravis: clinical characteristics, treatments, and outcome","volume":"9","author":"Cort\u00e9s-Vicente","year":"2022","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1001\/jamaneurol.2016.2032","article-title":"Clinical characteristics of patients with double-seronegative myasthenia gravis and antibodies to cortactin","volume":"73","author":"Cort\u00e9s-Vicente","year":"2016","journal-title":"JAMA Neurol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1002\/acn3.564","article-title":"The impact of rituximab infusion protocol on the long-term outcome in anti-MuSK myasthenia gravis","volume":"5","author":"Cort\u00e9s-Vicente","year":"2018","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1186\/s12974-020-01958-3","article-title":"Decreased expression of miR-29 family associated with autoimmune myasthenia gravis","volume":"17","author":"Cron","year":"2020","journal-title":"J. Neuroinflammation"},{"key":"B18","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1002\/mus.26695","article-title":"Cross-sectional analysis of the myasthenia gravis patient Registry: disability and treatment","volume":"60","author":"Cutter","year":"2019","journal-title":"Muscle Nerve"},{"key":"B19","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1097\/WCO.0000000000000858","article-title":"Progress in the therapy of myasthenia gravis: getting closer to effective targeted immunotherapies","volume":"33","author":"Dalakas","year":"2020","journal-title":"Curr. Opin. Neurol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"e1116","DOI":"10.1212\/NXI.0000000000001116","article-title":"IgG4-Mediated neurologic autoimmunities: understanding the pathogenicity of IgG4, ineffectiveness of IVIg, and long-lasting benefits of anti-B cell therapies","volume":"9","author":"Dalakas","year":"2021","journal-title":"Neurol. Neuroimmunol. Neuroinflamm"},{"key":"B21","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s40265-018-0875-9","article-title":"Eculizumab: a review in generalized myasthenia gravis","volume":"78","author":"Dhillon","year":"2018","journal-title":"Drugs"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1007\/s40265-021-01591-1","article-title":"Telitacicept: first approval","volume":"81","author":"Dhillon","year":"2021","journal-title":"Drugs"},{"key":"B23","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1016\/j.molimm.2009.04.009","article-title":"Structure of the Fab fragment of therapeutic antibody Ofatumumab provides insights into the recognition mechanism with CD20","volume":"46","author":"Du","year":"2009","journal-title":"Mol. Immunol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1007\/s00415-022-11048-4","article-title":"Individualized regimen of low-dose rituximab monotherapy for new-onset AChR-positive generalized myasthenia gravis","volume":"269","author":"Du","year":"2022","journal-title":"J. Neurol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1002\/ana.25708","article-title":"Severe neurological toxicity of immune checkpoint inhibitors: growing spectrum","volume":"87","author":"Dubey","year":"2020","journal-title":"Ann. Neurol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s40478-022-01454-0","article-title":"Reemergence of pathogenic, autoantibody-producing B cell clones in myasthenia gravis following B cell depletion therapy","volume":"10","author":"Fichtner","year":"2022","journal-title":"Acta Neuropathol. Commun."},{"key":"B27","doi-asserted-by":"publisher","first-page":"776","DOI":"10.3389\/fimmu.2020.00776","article-title":"Autoimmune pathology in myasthenia gravis disease subtypes is governed by divergent mechanisms of immunopathology","volume":"11","author":"Fichtner","year":"2020","journal-title":"Front. Immunol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1056\/NEJMra1602678","article-title":"Myasthenia gravis","volume":"375","author":"Gilhus","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/nrneurol.2016.44","article-title":"Myasthenia gravis - autoantibody characteristics and their implications for therapy","volume":"12","author":"Gilhus","year":"2016","journal-title":"Nat. Rev. Neurol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia gravis","volume":"5","author":"Gilhus","year":"2019","journal-title":"Nat. Rev. Dis. Prim."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","article-title":"Myasthenia gravis: subgroup classification and therapeutic strategies","volume":"14","author":"Gilhus","year":"2015","journal-title":"Lancet Neurol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1002\/mus.27140","article-title":"Reduced plasmablast frequency is associated with seronegative myasthenia gravis","volume":"63","author":"Guptill","year":"2021","journal-title":"Muscle Nerve"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1212\/WNL.0000000000004341","article-title":"Rituximab as treatment for anti-MuSK myasthenia gravis: multicenter blinded prospective review","volume":"89","author":"Hehir","year":"2017","journal-title":"Neurology"},{"key":"B34","doi-asserted-by":"publisher","first-page":"e1425","DOI":"10.1212\/WNL.0000000000005323","article-title":"Randomized study of adjunctive belimumab in participants with generalized myasthenia gravis","volume":"90","author":"Hewett","year":"2018","journal-title":"Neurology"},{"key":"B35","doi-asserted-by":"publisher","first-page":"835","DOI":"10.3389\/fimmu.2018.00835","article-title":"Targeting B cells and plasma cells in autoimmune diseases","volume":"9","author":"Hofmann","year":"2018","journal-title":"Front. Immunol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1111\/ene.13300","article-title":"Multiple antibody detection in 'seronegative' myasthenia gravis patients","volume":"24","author":"Hong","year":"2017","journal-title":"Eur. J. Neurol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/S1474-4422(23)00080-7","article-title":"Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study","volume":"22","author":"Howard","year":"2023","journal-title":"Lancet Neurol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"e2661","DOI":"10.1212\/WNL.0000000000007600","article-title":"Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis","volume":"92","author":"Howard","year":"2019","journal-title":"Neurology"},{"key":"B39","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet Neurol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"e357","DOI":"10.1212\/NXI.0000000000000357","article-title":"IgG-specific cell-based assay detects potentially pathogenic MuSK-Abs in seronegative MG","volume":"4","author":"Huda","year":"2017","journal-title":"Neurol. Neuroimmunol. Neuroinflamm"},{"key":"B42","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1111\/nyas.13561","article-title":"IgG4-mediated autoimmune diseases: a niche of antibody-mediated disorders","volume":"1413","author":"Huijbers","year":"2018","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"B43","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1007\/s11481-021-10004-9","article-title":"The role of plasma exchange in the treatment of refractory autoimmune neurological diseases: a narrative review","volume":"16","author":"Jacob","year":"2021","journal-title":"J. Neuroimmune Pharmacol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1001\/archneurol.2012.437","article-title":"Presence and pathogenic relevance of antibodies to clustered acetylcholine receptor in ocular and generalized myasthenia gravis","volume":"69","author":"Jacob","year":"2012","journal-title":"Arch. Neurol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.nmd.2017.03.007","article-title":"Beneficial effect of tocilizumab in myasthenia gravis refractory to rituximab","volume":"27","author":"Jonsson","year":"2017","journal-title":"Neuromuscul. Disord."},{"key":"B46","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.1111\/all.14704","article-title":"Systematic review of safety and efficacy of belimumab in treating immune-mediated disorders","volume":"76","author":"Kaegi","year":"2021","journal-title":"Allergy"},{"key":"B47","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.expneurol.2004.06.005","article-title":"Complement regulators in extraocular muscle and experimental autoimmune myasthenia gravis","volume":"189","author":"Kaminski","year":"2004","journal-title":"Exp. Neurol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1007\/s10072-015-2236-8","article-title":"Both binding and blocking antibodies correlate with disease severity in myasthenia gravis","volume":"36","author":"Kang","year":"2015","journal-title":"Neurol. Sci."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1212\/wnl.48.6.1638","article-title":"Reactivity of T cells from seronegative patients with myasthenia gravis to T cell epitopes of the human acetylcholine receptor","volume":"48","author":"Karni","year":"1997","journal-title":"Neurology"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1093\/brain\/aws025","article-title":"Muscle-specific kinase myasthenia gravis IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice","volume":"135","author":"Klooster","year":"2012","journal-title":"Brain"},{"key":"B51","doi-asserted-by":"publisher","first-page":"102646","DOI":"10.1016\/j.autrev.2020.102646","article-title":"Update on IgG4-mediated autoimmune diseases: new insights and new family members","volume":"19","author":"Koneczny","year":"2020","journal-title":"Autoimmun. Rev."},{"key":"B52","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jaut.2016.11.005","article-title":"IgG4 autoantibodies against muscle-specific kinase undergo Fab-arm exchange in myasthenia gravis patients","volume":"77","author":"Koneczny","year":"2017","journal-title":"J. Autoimmun."},{"key":"B53","doi-asserted-by":"publisher","first-page":"596981","DOI":"10.3389\/fneur.2020.596981","article-title":"Myasthenia gravis: autoantibody specificities and their role in MG management","volume":"11","author":"Lazaridis","year":"2020","journal-title":"Front. Neurol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/s41573-020-00092-2","article-title":"B cell depletion therapies in autoimmune disease: advances and mechanistic insights","volume":"20","author":"Lee","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"B55","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1002\/mus.27659","article-title":"One-year follow-up of disease burden and medication changes in patients with myasthenia gravis: from the MG Patient Registry","volume":"66","author":"Lee","year":"2022","journal-title":"Muscle Nerve"},{"key":"B56","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1001\/archneur.63.8.1066","article-title":"Plasma exchange in neuroimmunological disorders: part 2. Treatment of neuromuscular disorders","volume":"63","author":"Lehmann","year":"2006","journal-title":"Arch. Neurol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1093\/brain\/awn092","article-title":"IgG1 antibodies to acetylcholine receptors in 'seronegative' myasthenia gravis","volume":"131","author":"Leite","year":"2008","journal-title":"Brain"},{"key":"B58","doi-asserted-by":"publisher","first-page":"577528","DOI":"10.1016\/j.jneuroim.2021.577528","article-title":"Low-dose rituximab treatment for new-onset generalized myasthenia gravis","volume":"354","author":"Li","year":"","journal-title":"J. Neuroimmunol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.jocn.2020.11.043","article-title":"Efficacy and safety of different dosages of rituximab for refractory generalized AChR myasthenia gravis: a meta-analysis","volume":"85","author":"Li","year":"","journal-title":"J. Clin. Neurosci."},{"key":"B60","doi-asserted-by":"publisher","first-page":"116690","DOI":"10.1016\/j.jns.2020.116690","article-title":"Differential response to rituximab in anti-AChR and anti-MuSK positive myasthenia gravis patients: a single-center retrospective study","volume":"411","author":"Litchman","year":"2020","journal-title":"J. Neurol. Sci."},{"key":"B61","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/s41582-021-00547-z","article-title":"Getting specific: targeting Fc receptors in myasthenia gravis","volume":"17","author":"L\u00fcnemann","year":"2021","journal-title":"Nat. Rev. Neurol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s13023-023-02727-0","article-title":"Physician- and patient-reported perspectives on myasthenia gravis in Europe: a real-world survey","volume":"18","author":"Mahic","year":"2023","journal-title":"Orphanet J. Rare Dis."},{"key":"B63","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/1471-2474-15-178","article-title":"The effect of rituximab therapy on immunoglobulin levels in patients with multisystem autoimmune disease","volume":"15","author":"Marco","year":"2014","journal-title":"BMC Musculoskelet. Disord."},{"key":"B64","doi-asserted-by":"publisher","first-page":"613","DOI":"10.3389\/fimmu.2020.00613","article-title":"Long-lasting rituximab-induced reduction of specific-but not total-IgG4 in MuSK-positive myasthenia gravis","volume":"11","author":"Marino","year":"2020","journal-title":"Front. Immunol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/s0952-7915(99)80029-6","article-title":"B cell memory and the long-lived plasma cell","volume":"11","author":"McHeyzer-Williams","year":"1999","journal-title":"Curr. Opin. Immunol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"e1617","DOI":"10.1212\/WNL.0000000000010574","article-title":"Patient-acceptable symptom states in myasthenia gravis","volume":"95","author":"Mendoza","year":"2020","journal-title":"Neurology"},{"key":"B67","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1007\/s40265-022-01726-y","article-title":"Pharmacotherapy of generalized myasthenia gravis with special emphasis on newer biologicals","volume":"82","author":"Menon","year":"2022","journal-title":"Drugs"},{"key":"B68","doi-asserted-by":"publisher","first-page":"3904","DOI":"10.1007\/s00415-022-11023-z","article-title":"Seronegative myasthenic crisis: a multicenter analysis","volume":"269","author":"Mergenthaler","year":"2022","journal-title":"J. Neurol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"19","DOI":"10.17161\/rrnmf.v3i1.14989","article-title":"Characteristics of triple seronegative myasthenia gravis: a single center experience","volume":"3","author":"Morena","year":"2022","journal-title":"rrnmf"},{"key":"B70","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/mus.26447","article-title":"Long-term safety and efficacy of eculizumab in generalized myasthenia gravis","volume":"60","author":"Muppidi","year":"2019","journal-title":"Muscle Nerve"},{"key":"B71","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2147\/ITT.S377056","article-title":"Novel immunotherapies for myasthenia gravis","volume":"12","author":"Nair","year":"2023","journal-title":"Immunotargets Ther."},{"key":"B72","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","article-title":"International consensus guidance for management of myasthenia gravis: 2020 update","volume":"96","author":"Narayanaswami","year":"2021","journal-title":"Neurology"},{"key":"B73","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1056\/NEJMoa1311084","article-title":"Genetic variants in C5 and poor response to eculizumab","volume":"370","author":"Nishimura","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"B74","doi-asserted-by":"publisher","first-page":"e376","DOI":"10.1212\/WNL.0000000000013121","article-title":"Phase 2 trial of rituximab in acetylcholine receptor antibody-positive generalized myasthenia gravis: the BeatMG study","volume":"98","author":"Nowak","year":"2021","journal-title":"Neurology"},{"key":"B75","doi-asserted-by":"publisher","first-page":"e1382","DOI":"10.1212\/WNL.0000000000012604","article-title":"Patient-reported symptom severity in a nationwide myasthenia gravis cohort: cross-sectional analysis of the Swedish GEMG study","volume":"97","author":"Petersson","year":"2021","journal-title":"Neurology"},{"key":"B76","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1001\/jamaneurol.2022.2887","article-title":"Efficacy and safety of rituximab for new-onset generalized myasthenia gravis: the RINOMAX randomized clinical trial","volume":"79","author":"Piehl","year":"2022","journal-title":"JAMA Neurol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1212\/01.wnl.0000041625.41937.ff","article-title":"AChR phosphorylation and indirect inhibition of AChR function in seronegative MG","volume":"59","author":"Plested","year":"2002","journal-title":"Neurology"},{"key":"B78","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1002\/mus.26985","article-title":"Clinical features of LRP4\/agrin-antibody-positive myasthenia gravis: a multicenter study","volume":"62","author":"Rivner","year":"2020","journal-title":"Muscle Nerve"},{"key":"B79","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/nri2155","article-title":"FcRn: the neonatal Fc receptor comes of age","volume":"7","author":"Roopenian","year":"2007","journal-title":"Nat. Rev. Immunol."},{"key":"B80","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis: executive summary","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology"},{"key":"B81","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1080\/08923973.2021.1973493","article-title":"Telitacicept as a BLyS\/APRIL dual inhibitor for autoimmune disease","volume":"43","author":"Shi","year":"2021","journal-title":"Immunopharmacol. Immunotoxicol."},{"key":"B82","doi-asserted-by":"publisher","first-page":"553","DOI":"10.2217\/imt-2022-0298","article-title":"Clinical efficacy and safety of efgartigimod for treatment of myasthenia gravis","volume":"15","author":"Sivadasan","year":"2023","journal-title":"Immunotherapy"},{"key":"B83","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1007\/s13311-022-01196-w","article-title":"Evolution of anti-B cell therapeutics in autoimmune neurological diseases","volume":"19","author":"Stathopoulos","year":"2022","journal-title":"Neurotherapeutics"},{"key":"B84","doi-asserted-by":"publisher","first-page":"e94263","DOI":"10.1172\/jci.insight.94263","article-title":"Autoantibody-producing plasmablasts after B cell depletion identified in muscle-specific kinase myasthenia gravis","volume":"2","author":"Stathopoulos","year":"2017","journal-title":"JCI Insight"},{"key":"B85","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.jneuroim.2016.01.018","article-title":"Titin antibodies in \"seronegative\" myasthenia gravis--A new role for an old antigen","volume":"292","author":"Stergiou","year":"2016","journal-title":"J. Neuroimmunol."},{"key":"B86","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1002\/mus.25597","article-title":"Rituximab treatment of myasthenia gravis: a systematic review","volume":"56","author":"Tandan","year":"2017","journal-title":"Muscle Nerve"},{"key":"B87","doi-asserted-by":"publisher","first-page":"4372","DOI":"10.1172\/JCI97911","article-title":"Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans","volume":"128","author":"Ulrichts","year":"2018","journal-title":"J. Clin. Investig."},{"key":"B88","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1126\/science.1144603","article-title":"Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange","volume":"317","author":"van der Neut Kolfschoten","year":"2007","journal-title":"Science"},{"key":"B89","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/s1474-4422(03)00306-5","article-title":"Seronegative generalised myasthenia gravis: clinical features, antibodies, and their targets","volume":"2","author":"Vincent","year":"2003","journal-title":"Lancet Neurol."},{"key":"B90","doi-asserted-by":"publisher","first-page":"EVIDoa2100066","DOI":"10.1056\/EVIDoa2100066","article-title":"Terminal complement inhibitor ravulizumab in generalized myasthenia gravis","volume":"1","author":"Vu","year":"2022","journal-title":"NEJM Evid."},{"key":"B91","doi-asserted-by":"publisher","first-page":"3129","DOI":"10.1007\/s00415-023-11617-1","article-title":"Ravulizumab pharmacokinetics and pharmacodynamics in patients with generalized myasthenia gravis","volume":"270","author":"Vu","year":"2023","journal-title":"J. Neurol."},{"key":"B92","doi-asserted-by":"publisher","first-page":"1321058","DOI":"10.3389\/fneur.2024.1321058","article-title":"Case report: recovery from refractory myasthenic crisis to minimal symptom expression after add-on treatment with efgartigimod","volume":"15","author":"Watanabe","year":"2024","journal-title":"Front. Neurol."},{"key":"B93","doi-asserted-by":"publisher","first-page":"E45-E47","DOI":"10.1002\/mus.26707","article-title":"Refractory myasthenia gravis successfully treated with ofatumumab","volume":"60","author":"Waters","year":"2019","journal-title":"Muscle Nerve"},{"key":"B94","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1002\/cpdd.1136","article-title":"Pharmacokinetic characteristics, safety, and tolerability of telitacicept, an injectable recombinant human B-lymphocyte stimulating factor receptor-antibody fusion protein, in healthy Chinese subjects","volume":"11","author":"Xie","year":"2022","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"B95","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1007\/s40120-022-00345-9","article-title":"Therapeutic effects of batoclimab in Chinese patients with generalized myasthenia gravis: a double-blinded, randomized, placebo-controlled phase II study","volume":"11","author":"Yan","year":"2022","journal-title":"Neurol. Ther."},{"key":"B96","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1002\/mus.25973","article-title":"B cells in the pathophysiology of myasthenia gravis","volume":"57","author":"Yi","year":"2018","journal-title":"Muscle Nerve"},{"key":"B97","doi-asserted-by":"publisher","first-page":"686466","DOI":"10.3389\/fimmu.2021.686466","article-title":"Short- and long-lived autoantibody-secreting cells in autoimmune neurological disorders","volume":"12","author":"Zografou","year":"2021","journal-title":"Front. Immunol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1370411\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,19]],"date-time":"2024-07-19T10:31:24Z","timestamp":1721385084000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1370411\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,27]]},"references-count":97,"alternative-id":["10.3389\/fphar.2024.1370411"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1370411","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,27]]},"article-number":"1370411"}}